May 5, 2026 — Leads & Copy — Alkermes plc (Nasdaq: ALKS) has released its financial results for the quarter ending March 31, 2026, and has also shared its financial expectations for the full year 2026.
A detailed first quarter 2026 earnings press release and presentation can be found on the company’s investor relations website.
Alkermes is hosting a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) today to discuss these financial results and expectations and provide an update on the company. The webcast can be accessed on the Investors section of Alkermes’ website. The conference call can be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. A replay of the conference call will also be available on Alkermes’ website.
Alkermes plc is a global biopharmaceutical company focused on developing medicines in neuroscience. It has commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder, and narcolepsy. Alkermes’ pipeline includes late-stage clinical candidates in development for narcolepsy and idiopathic hypersomnia, and orexin 2 receptor agonists in early clinical development for other neurological disorders, including ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease.
Headquartered in Ireland, Alkermes also has a corporate office and research and development center in Massachusetts and a manufacturing facility in Ohio.
Source: Alkermes
